1 to 10 of 72 literature results

• Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

  BACKGROUND: Because the efficacy of carboplatin and cisplatin in the treatment of advanced non-small-cell lung cancer (NSCLC) has not been proven to b…

  Authors: Andrea Ardizzoni, Luca Boni, Marcello Tiseo, Frank V Fossella, Joan H Schiller, Marianne Paesmans, Davorin Radosavljevic, Adriano Paccagnella, Petr Zatloukal, Paola Mazzanti,…

  Source: Journal of the National Cancer Institute. 2007 Jun 6

  View Full Text

• Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).

  Expression of epidermal growth factor and its transmembrane receptor (EGFR) stimulates tumor growth. Matuzumab is a humanized anti-EGFR monoclonal ant…

  Authors: Joan H Schiller

  Source: Cancer investigation. 2008 Feb

  View Full Text

• New directions for ZD1839 in the treatment of solid tumors.

  Among molecular mechanisms of tumor growth and progression, activated epidermal growth factor receptor-tyrosine kinase is remarkable for its prevalenc…

  Authors: Joan H Schiller

  Source: Seminars in oncology. 2003 Feb

  View Full Text

• Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.

  BACKGROUND: Demographic factors and treatment regimens were evaluated in relation to differences in outcome between patients with advanced nonsmall ce…

  Authors: Heather A Wakelee, Patricia Bernardo, David H Johnson, Joan H Schiller

  Source: Cancer. 2006 May 15

  View Full Text

• Using liquid crystals to report membrane proteins captured by affinity microcontact printing from cell lysates and membrane extracts.

  The chemical heterogeneity of proteins makes development of general and facile surface-based methods for protein analysis a substantial challenge, par…

  Authors: Chang-Hyun Jang, Matthew L Tingey, Nichole L Korpi, Gregory J Wiepz, Joan H Schiller, Paul J Bertics, Nicholas L Abbott

  Source: Journal of the American Chemical Society. 2005 Jun 29

  View Full Text

• A phase II trial of Triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

  BACKGROUND: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. METHODS:…

  Authors: Anne M Traynor, Ju-Whei Lee, Gerald K Bayer, John M Tate, Sachdev P Thomas, Miroslaw Mazurczak, David L Graham, Jill M Kolesar, Joan H Schiller

  Source: Investigational new drugs. 2010 Feb

  View Full Text

• Small cell lung cancer: defining a role for emerging platinum drugs.

  Small cell lung cancer (SCLC) is characterized by early dissemination and a rapid, aggressive clinical course. It has, however, marked susceptibility …

  Authors: Joan H Schiller

  Source: Oncology. 2002

  View Full Text

• Epidermal growth factor receptor as a therapeutic target in lung cancer.

  Almost two decades of research to determine how cancer cells differ from noncancerous cells at the molecular level have been richly rewarding. Several…

  Authors: Joan H Schiller

  Source: Seminars in respiratory and critical care medicine. 2004

  View Full Text

• Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

  PURPOSE Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) with demonstrated efficacy in combination with car…

  Authors: Suzanne E Dahlberg, Alan B Sandler, Julie R Brahmer, Joan H Schiller, David H Johnson

  Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Feb 20

  View Full Text

• Perceived stigma, self-blame, and adjustment among lung, breast and prostate cancer patients.

  People who suffer from disease have often been stigmatised. The internalisation of stigma leads to the experience of self-blame. The relationship amon…

  Authors: Nicole M Else-Quest, Noelle K LoConte, Joan H Schiller, Janet Shibley Hyde

  Source: Psychology & health. 2009 Oct

  View Full Text